(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3S)-3-se-butoxy-2-((S)-2-hydroxy-5-oxo-tetrahydrofuran-3-ylcarbamoyl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835313

PubChem CID: 56663392

Max Phase: Preclinical

Molecular Formula: C29H47N5O11

Molecular Weight: 641.72

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CCC(C)O[C@H]1CCN(C(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(C)=O)C(C)C)C(C)C)[C@@H]1C(=O)N[C@H]1CC(=O)OC1O

Standard InChI: InChI=1S/C29H47N5O11/c1-8-15(6)44-19-9-10-34(24(19)27(41)32-18-12-21(38)45-29(18)43)28(42)23(14(4)5)33-25(39)17(11-20(36)37)31-26(40)22(13(2)3)30-16(7)35/h13-15,17-19,22-24,29,43H,8-12H2,1-7H3,(H,30,35)(H,31,40)(H,32,41)(H,33,39)(H,36,37)/t15?,17-,18-,19-,22-,23-,24-,29?/m0/s1

Standard InChI Key: DKZCVXXTAXUVCL-OWVMPFOQSA-N

Molfile:

     RDKit          2D

 45 46  0  0  0  0  0  0  0  0999 V2000
   29.1058   -6.7958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4321   -7.2720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6763   -8.0610    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.5024   -8.0749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7667   -7.2922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.9801   -8.7475    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   27.6547   -7.0086    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.1218   -5.9712    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.3694   -5.6274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.7085   -4.3147    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.3739   -4.8024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0445   -4.3218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.7925   -3.5335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.9683   -3.5329    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5665   -4.3147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2782   -3.9022    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.8506   -3.9022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5665   -5.1397    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.9940   -4.3147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.7099   -3.9022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9940   -5.1397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2782   -5.5522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.7099   -5.5522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.4216   -4.3147    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.7099   -3.0772    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.1375   -3.9022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8533   -4.3147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1375   -3.0772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8533   -5.1397    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.8533   -2.6647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5700   -3.0783    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.8541   -1.8408    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.5650   -3.9022    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.2809   -4.3147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.9926   -3.9022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.2809   -5.1397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5650   -5.5522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.9926   -5.5522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.9926   -3.0772    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   27.6741   -6.0714    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.8259   -4.5760    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.5316   -4.1486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.5143   -3.3238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.2545   -4.5460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.2200   -2.8964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
 11  9  1  1
  1  5  1  0
  4  6  2  0
  2  7  1  0
  1  8  1  1
  9  8  1  0
 10 11  1  0
  1  2  1  0
  2  3  1  0
 15 16  1  0
 15 17  1  0
 15 18  2  0
 16 19  1  0
 19 20  1  0
 19 21  1  6
 21 22  1  0
 21 23  1  0
 20 24  1  0
 20 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  1  1
 27 29  2  0
 28 30  1  0
 30 31  1  0
 30 32  2  0
 27 33  1  0
 33 34  1  0
 34 35  1  0
 34 36  1  6
 36 37  1  0
 36 38  1  0
 35 10  1  0
 35 39  2  0
  3  4  1  0
  9 40  2  0
  4  5  1  0
 12 41  1  6
 11 12  1  0
 41 42  1  0
 12 13  1  0
 42 43  1  0
 13 14  1  0
 42 44  1  0
 14 10  1  0
 43 45  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)

Discover Target: CASP2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CASP3 Tchem Caspase-3 (3632 Activities)

Discover Target: CASP3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 641.72	Molecular Weight (Monoisotopic): 641.3272	AlogP: -1.22	#Rotatable Bonds: 15
Polar Surface Area: 229.77	Molecular Species: ACID	HBA: 10	HBD: 6
#RO5 Violations: 2	HBA (Lipinski): 16	HBD (Lipinski): 6	#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.26	CX Basic pKa: ┄	CX LogP: -1.37	CX LogD: -4.37
Aromatic Rings: ┄	Heavy Atoms: 45	QED Weighted: 0.12	Np Likeness Score: 0.40

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C.. (2011) Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors., 19 (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors. 2006-03-09 Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors. 2011-10-01 Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors. [PMID:21903398]

(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3S)-3-se-butoxy-2-((S)-2-hydroxy-5-oxo-tetrahydrofuran-3-ylcarbamoyl)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source